iZafe Group AB Series B

IZAFE-B · Nasdaq Stockholm · Healthcare

0.33SEK +11.7%last day

Price as of 2 October 2026

The price over the past year, with dividends: −26.1%

Performance

1 month

+4.4%

1 year

−26.1%

3 years, per year

+10.3%

5 years, per year

−27.2%

Largest fall, 3 years

−94.0%

Below the peak now

−97.8%

Volatility, 1 year

78.7%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

7.9

Dividend yield

0.0%

Return on equity

−130.1%

Net margin

−143.2%

Market value

14 m USD

Quality, value and trend

Where iZafe Group stands against every Nordic stock today. 100 is best.

Quality26

Profitability and a sound balance sheet over time. Better than 26% of Nordic stocks.

Value3

The price measured against earnings, assets and cash flow. Better than 3% of Nordic stocks.

Trend26

The price development over the past year. Better than 26% of Nordic stocks.

Combined4

Quality, value and trend together. Better than 4% of Nordic stocks.

About iZafe Group

iZafe Group AB Series B is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 14 employees.

iZafe Group AB (publ), a medical technology company, develops and markets medical and digital security solutions in Sweden and internationally. It offers Dosell, an automated medication dispenser for medication at home; and Pilloxa, an app for clinical studies, as well as to engage and involve patients. The company was formerly known as MediRätt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis